AwardedSpainGoodsDynamic purchasing system€2,434,682
4ª Prorroga Suministro de NATALIZUMAB jeringa (TYSABRI) y DIROXIMEL FUMARATO cápsula (VUMERITY) de distribución exclusiva con destino al Servicio de Farmacia del Hospital Clínico San Carlos de Madrid
- Published
- Published 5 August 2025
Overview
Hospital Clínico San Carlos awarded BIOGEN SPAIN S.L. a contract for the fourth extension of exclusive supply of NATALIZUMAB (TYSABRI) syringes and DIROXIMEL FUMARATE (VUMERITY) capsules to its pharmacy service, valued at €325,569.66 as of 27 May 2026. The original estimated value for the full procurement framework was €2,434,682.33.
Key details
- Country
- Spain
- Status
- Awarded
- Category
- Goods
- Estimated value
- €2,434,682
- Procedure
- Direct
- Contract type
- Dynamic purchasing system
- Published
- 5 August 2025
Pharmaceutical products
Award outcome
- Awarded value
- €325,570
- Award date
- 27 May 2026
- Contract period
- 27 May 2026 → 23 November 2026
- BIOGEN SPAIN S.L.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
28 May 2026
Contract Award Notice
5 May 2026
Contract Award Notice
5 February 2026
Contract Award Notice
5 August 2025
Contracting authority
Hospital Clinico San Carlos
Procuring entityMADRID, Spain
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.